Skip to main content
Erschienen in: European Child & Adolescent Psychiatry 11-12/2011

01.12.2011 | Editorial

What does it mean? Looking beyond group differences in clinical research

verfasst von: David Coghill

Erschienen in: European Child & Adolescent Psychiatry | Ausgabe 11-12/2011

Einloggen, um Zugang zu erhalten

Excerpt

It is usual practice for scientific papers to focus on the description of groups of subjects in terms of their mean scores on a particular measure and to assess differences between these groups by comparing these means using standard statistical tests. When we read that, "compared to a control group, those with a particular disorder or problem scored significantly higher on a symptom questionnaire", or "performed less well on a particular neuropsychological task", or that "those patients treated with an active treatment had lower symptom scores at the end of the trial than those treated with a placebo", we are able to make certain assumptions about that disorder or treatment. If we are interested in the strength of an effect we will often look to the effect size for an answer. There is no doubt that incorporating information derived from such comparisons is not only appropriate but forms the basis of evidence-based clinical practice. However, sometimes it is informative to look beyond the means and consider the heterogeneity and inter-individual variability that is often seen across many levels of analysis including symptoms, cognition and more basic causal processes. …
Literatur
1.
Zurück zum Zitat Barkley RA (1997) Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 121:65–94PubMedCrossRef Barkley RA (1997) Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 121:65–94PubMedCrossRef
2.
Zurück zum Zitat Coghill DR, Rhodes SM, Matthews K (2007) The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder. Biol Psychiatry 62:954–962PubMedCrossRef Coghill DR, Rhodes SM, Matthews K (2007) The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder. Biol Psychiatry 62:954–962PubMedCrossRef
3.
Zurück zum Zitat Jacobson NS, Truax P (1991) Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 59:12–19PubMedCrossRef Jacobson NS, Truax P (1991) Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 59:12–19PubMedCrossRef
4.
Zurück zum Zitat Nigg JT, Willcutt EG, Doyle AE, Sonuga-Barke EJ (2005) Causal heterogeneity in attention-deficit/hyperactivity disorder: do we need neuropsychologically impaired subtypes? Biol Psychiatry 57:1224–1230PubMedCrossRef Nigg JT, Willcutt EG, Doyle AE, Sonuga-Barke EJ (2005) Causal heterogeneity in attention-deficit/hyperactivity disorder: do we need neuropsychologically impaired subtypes? Biol Psychiatry 57:1224–1230PubMedCrossRef
5.
Zurück zum Zitat Sonuga-Barke E, Bitsakou P, Thompson M (2010) Beyond the dual pathway model: evidence for the dissociation of timing, inhibitory, and delay-related impairments in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 49:345–355PubMed Sonuga-Barke E, Bitsakou P, Thompson M (2010) Beyond the dual pathway model: evidence for the dissociation of timing, inhibitory, and delay-related impairments in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 49:345–355PubMed
6.
Zurück zum Zitat Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J (2003) Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Safety Int J Med Toxicol Drug Exp 26:729–740CrossRef Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J (2003) Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Safety Int J Med Toxicol Drug Exp 26:729–740CrossRef
Metadaten
Titel
What does it mean? Looking beyond group differences in clinical research
verfasst von
David Coghill
Publikationsdatum
01.12.2011
Verlag
Springer-Verlag
Erschienen in
European Child & Adolescent Psychiatry / Ausgabe 11-12/2011
Print ISSN: 1018-8827
Elektronische ISSN: 1435-165X
DOI
https://doi.org/10.1007/s00787-011-0222-0

Weitere Artikel der Ausgabe 11-12/2011

European Child & Adolescent Psychiatry 11-12/2011 Zur Ausgabe

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.